Weekly Recap

Bexicaserin Improves Seizure Control in DEEs, SPN-830 Approved for Parkinson Disease, Self-Administration Rozanolixizumab Gains EU Approval

ByNeurologyLive® Staff

February 9th 2025

Neurology News Network. for the week ending February 9, 2025. [WATCH TIME: 4 minutes]

MSA Agent ATH434 Shows Promising Phase 2 Data, FDA Approves Suzetrigine for Severe Acute Pain, AXS-07 Gains FDA Approval for Migraine

ByNeurologyLive® Staff

February 2nd 2025

Neurology News Network. for the week ending February 2, 2025. [WATCH TIME: 4 minutes]

FDA Accepts sNDA for Higher Dose Nusinersen, Tofersen Demonstrates Real-World Efficacy, Nipocalimab Gains Priority Review

ByNeurologyLive® Staff

January 25th 2025

Neurology News Network. for the week ending January 25, 2025. [WATCH TIME: 4 minutes]

FDA Accepts NDA for Lecanemab Subcutaneous Autoinjector, RAP-219 Shows Promise in Early Trials, Blarcamesine Treatment Effects Observed at 3 Years

ByNeurologyLive® Staff

January 18th 2025

Neurology News Network. for the week ending January 18, 2025. [WATCH TIME: 4 minutes]

Anti-Tau Therapy Posdinemab Gets Fast Track, Gene Therapy SGT-212 to Enter Friedreich Ataxia Trial, Zorevunersen Eyes Phase 3 Trial of Dravet

ByNeurologyLive® Staff

January 11th 2025

Neurology News Network. for the week ending January 11, 2025. [WATCH TIME: 4 minutes]

Intrathecal Zolgensma Meets Primary End Point, Deramiocel BLA Submitted, Imlifidase Improves Function in Guillain-Barré Syndrome

ByNeurologyLive® Staff

January 4th 2025

Neurology News Network. for the week ending January 4, 2025. [WATCH TIME: 4 minutes]

FDA Places Hold on CONNECT2-EDO51, Sevasemten Meets End Point in Becker, Tolebrutinib Gets Breakthrough Therapy Designation

ByNeurologyLive® Staff

December 21st 2024

Neurology News Network. for the week ending December 21, 2024. [WATCH TIME: 4 minutes]

RELIEV2-CM Study Launched, Dose-Finding Portion of ANQUR Underway, Anavex Submits EU Application for Blarcamesine

ByNeurologyLive® Staff

December 7th 2024

Neurology News Network. for the week ending December 7, 2024. [WATCH TIME: 4 minutes]

Alzheimer Agent Simufilam Fails Phase 3, Lamotrigine Trial in DLB, Hearing Loss Independent Risk Factor for Parkinson

ByNeurologyLive® Staff

November 30th 2024

Neurology News Network. for the week ending November 30, 2024. [WATCH TIME: 4 minutes]

Parkinson Agent Solengepras Enters Phase 3, Sage to Discontinue SAGE-718, Serious Adverse Event Reported in Gene Therapy Study of NGN-401

ByNeurologyLive® Staff

November 23rd 2024

Neurology News Network. for the week ending November 23, 2024. [WATCH TIME: 4 minutes]

FDA Clears ARIA Detecting Software, Nerivio Gains Expanded Indication, FDA Approves First-Ever Gene Therapy for AADC Deficiency

ByNeurologyLive® Staff

November 16th 2024

Neurology News Network. for the week ending November 9, 2024. [WATCH TIME: 4 minutes]

FDA Places Hold on RAP-219, cAPPricorn-1 Study to Assess Mivelsiran in CAA, FDA Accepts Resubmitted NDA for Ataluren

ByNeurologyLive® Staff

November 9th 2024

Neurology News Network. for the week ending November 9, 2024. [WATCH TIME: 4 minutes]

Enhanced Dosing of Donanemab Lowers ARIA Risk, Anti-Tau Agent E2814 Shows Promising Results, Combination Approach of Intranasal Insulin and Empagliflozin

ByNeurologyLive® Staff

November 2nd 2024

Neurology News Network. for the week ending November 2, 2024. [WATCH TIME: 4 minutes]

Phase 3 Program of Vidofludimus Calcium Continues, CHMP Recommends Approval for Eplontersen, Patient Dosing Commenced in Phase 1/2 Trial of ATX-01

ByNeurologyLive® Staff

October 26th 2024

Neurology News Network. for the week ending October 26, 2024. [WATCH TIME: 4 minutes]

FDA Approves Lumyrz for Pediatric Narcolepsy, 24-Hour Foslevodopa/Foscarbidopa Gets FDA Greenlight, Oral Edaravone Fails in Phase 3 Study

ByNeurologyLive® Staff

October 19th 2024

Neurology News Network. for the week ending October 19, 2024. [WATCH TIME: 4 minutes]

HNSA-5487 Significantly Reduces IgG Levels, FDA Removes Hold on AOC 1001, DMD Gene Therapy Shows No Impact on Cardiac Outcomes

ByNeurologyLive® Staff

October 12th 2024

Neurology News Network. for the week ending October 12, 2024. [WATCH TIME: 4 minutes]

Horizon Study Update for MSA Drug ION464, OnaboutlinumtoxinA to be Tested in Essential Tremor, Challenges With Ketogenic-Mediterranean Diets in PD

ByNeurologyLive® Staff

October 5th 2024

Neurology News Network. for the week ending October 5, 2024. [WATCH TIME: 4 minutes]

Positive Phase 2 FORWARD-53 Data of WVE-N531, RNS60 Extends Survival in ALS, BLA to be Submitted for Deramiocel

ByNeurologyLive® Staff

September 28th 2024

Neurology News Network. for the week ending September 28, 2024. [WATCH TIME: 4 minutes]

New BREAKTHROUGH Study of BMB-101, Positive Phase 1 Data on Orexin Agonist ORX750, Dosing Commenced for QRL-101

ByNeurologyLive® Staff

September 21st 2024

Neurology News Network. for the week ending September 21, 2024. [WATCH TIME: 4 minutes]

FDA Supports A-Synuclein Assay for PD Trials, VES001 Meets Primary End Point, Digital Migraine Therapeutic CT-132 Performs

ByNeurologyLive® Staff

September 14th 2024

Neurology News Network. for the week ending September 14, 2024. [WATCH TIME: 4 minutes]

Tolebrutinib Shows Promise in Non-Relapsing Secondary Progressive MS, Fenebrutinib Suppresses Relapses in New Data, FDA Accepts Resubmitted NDA for AXS-07

ByNeurologyLive® Staff

September 7th 2024

Neurology News Network. for the week ending September 7, 2024. [WATCH TIME: 4 minutes]

AMX0035's Potential in Tauopathies, Alkermes Initiates Phase 2 Study of ALKS 2680, EryDex Falls Short in Phase 3 ATTeST Trial

ByNeurologyLive® Staff

August 31st 2024

Neurology News Network. for the week ending August 31, 2024. [WATCH TIME: 4 minutes]

Medtronic DBS Approved for Asleep Surgery, BHV-2100 Shows Early Promise, AOC 1044 Continues Dystrophin Production in Latest Update

ByNeurologyLive® Staff

August 17th 2024

Neurology News Network. for the week ending August 17, 2024. [WATCH TIME: 4 minutes]

IND Cleared for Cell Therapy in Progressive MS, FDA Approves IPX203, Migraine Treatment Nerivio Safe in Pediatric Populations

ByNeurologyLive® Staff

August 10th 2024

Neurology News Network. for the week ending August 10, 2024. [WATCH TIME: 4 minutes]

ALPHA-1062 Approved for Alzheimer Disease, GLP-1 Agonist Shows Neuroprotective Effects Against Dementia, Lecanemab 3-Year Data Reported

ByNeurologyLive® Staff

August 4th 2024

Neurology News Network. for the week ending August 3, 2024. [WATCH TIME: 4 minutes]

Cerliponase Alfa Approved for All Ages of CLN2 Disease, SAGE-324 Discontinued, ION582 to Advance to Phase 3 in Angelman Syndrome

ByNeurologyLive® Staff

July 28th 2024

Neurology News Network. for the week ending July 27, 2024. [WATCH TIME: 4 minutes]

LX2006 Improves Cardiac Biomarkers of FA, ATH434 Positive Results in MSA, Brivaracetam Effective Regardless of Intellectual Disabilities

ByNeurologyLive® Staff

July 14th 2024

Neurology News Network. for the week ending July 20, 2024. [WATCH TIME: 4 minutes]

SKY-0515 Shows Significant HTT Reduction, AMT-130 Slows Huntington Progression, Capricor to Meet With FDA on CAP-1002

ByNeurologyLive® Staff

July 14th 2024

Neurology News Network. for the week ending July 13, 2024. [WATCH TIME: 4 minutes]

AFFINITY DUCHENNE Trial Expands, Suvecaltamide Fails Phase 2b Study of Essential Tremor, PTC518 Shows Dose-Dependent Huntingtin Lowering

ByNeurologyLive® Staff

July 7th 2024

Neurology News Network. for the week ending July 6, 2024. [WATCH TIME: 4 minutes]

ABBV-951 Gets Another CRL, Pitolisant Approved for Pediatric Narcolepsy, FDA Clears Efgartigimod for CIDP

ByNeurologyLive® Staff

June 30th 2024

Neurology News Network. for the week ending June 29, 2024. [WATCH TIME: 3 minutes]

Weekly Recap

Bexicaserin Improves Seizure Control in DEEs, SPN-830 Approved for Parkinson Disease, Self-Administration Rozanolixizumab Gains EU Approval

MSA Agent ATH434 Shows Promising Phase 2 Data, FDA Approves Suzetrigine for Severe Acute Pain, AXS-07 Gains FDA Approval for Migraine

FDA Accepts sNDA for Higher Dose Nusinersen, Tofersen Demonstrates Real-World Efficacy, Nipocalimab Gains Priority Review

FDA Accepts NDA for Lecanemab Subcutaneous Autoinjector, RAP-219 Shows Promise in Early Trials, Blarcamesine Treatment Effects Observed at 3 Years

Anti-Tau Therapy Posdinemab Gets Fast Track, Gene Therapy SGT-212 to Enter Friedreich Ataxia Trial, Zorevunersen Eyes Phase 3 Trial of Dravet

Intrathecal Zolgensma Meets Primary End Point, Deramiocel BLA Submitted, Imlifidase Improves Function in Guillain-Barré Syndrome

FDA Places Hold on CONNECT2-EDO51, Sevasemten Meets End Point in Becker, Tolebrutinib Gets Breakthrough Therapy Designation

RELIEV2-CM Study Launched, Dose-Finding Portion of ANQUR Underway, Anavex Submits EU Application for Blarcamesine

Alzheimer Agent Simufilam Fails Phase 3, Lamotrigine Trial in DLB, Hearing Loss Independent Risk Factor for Parkinson

Parkinson Agent Solengepras Enters Phase 3, Sage to Discontinue SAGE-718, Serious Adverse Event Reported in Gene Therapy Study of NGN-401

FDA Clears ARIA Detecting Software, Nerivio Gains Expanded Indication, FDA Approves First-Ever Gene Therapy for AADC Deficiency

FDA Places Hold on RAP-219, cAPPricorn-1 Study to Assess Mivelsiran in CAA, FDA Accepts Resubmitted NDA for Ataluren

Enhanced Dosing of Donanemab Lowers ARIA Risk, Anti-Tau Agent E2814 Shows Promising Results, Combination Approach of Intranasal Insulin and Empagliflozin

Phase 3 Program of Vidofludimus Calcium Continues, CHMP Recommends Approval for Eplontersen, Patient Dosing Commenced in Phase 1/2 Trial of ATX-01

FDA Approves Lumyrz for Pediatric Narcolepsy, 24-Hour Foslevodopa/Foscarbidopa Gets FDA Greenlight, Oral Edaravone Fails in Phase 3 Study

HNSA-5487 Significantly Reduces IgG Levels, FDA Removes Hold on AOC 1001, DMD Gene Therapy Shows No Impact on Cardiac Outcomes

Horizon Study Update for MSA Drug ION464, OnaboutlinumtoxinA to be Tested in Essential Tremor, Challenges With Ketogenic-Mediterranean Diets in PD

Positive Phase 2 FORWARD-53 Data of WVE-N531, RNS60 Extends Survival in ALS, BLA to be Submitted for Deramiocel

New BREAKTHROUGH Study of BMB-101, Positive Phase 1 Data on Orexin Agonist ORX750, Dosing Commenced for QRL-101

FDA Supports A-Synuclein Assay for PD Trials, VES001 Meets Primary End Point, Digital Migraine Therapeutic CT-132 Performs

Tolebrutinib Shows Promise in Non-Relapsing Secondary Progressive MS, Fenebrutinib Suppresses Relapses in New Data, FDA Accepts Resubmitted NDA for AXS-07

AMX0035's Potential in Tauopathies, Alkermes Initiates Phase 2 Study of ALKS 2680, EryDex Falls Short in Phase 3 ATTeST Trial

Medtronic DBS Approved for Asleep Surgery, BHV-2100 Shows Early Promise, AOC 1044 Continues Dystrophin Production in Latest Update

IND Cleared for Cell Therapy in Progressive MS, FDA Approves IPX203, Migraine Treatment Nerivio Safe in Pediatric Populations

ALPHA-1062 Approved for Alzheimer Disease, GLP-1 Agonist Shows Neuroprotective Effects Against Dementia, Lecanemab 3-Year Data Reported

Cerliponase Alfa Approved for All Ages of CLN2 Disease, SAGE-324 Discontinued, ION582 to Advance to Phase 3 in Angelman Syndrome

LX2006 Improves Cardiac Biomarkers of FA, ATH434 Positive Results in MSA, Brivaracetam Effective Regardless of Intellectual Disabilities

SKY-0515 Shows Significant HTT Reduction, AMT-130 Slows Huntington Progression, Capricor to Meet With FDA on CAP-1002

AFFINITY DUCHENNE Trial Expands, Suvecaltamide Fails Phase 2b Study of Essential Tremor, PTC518 Shows Dose-Dependent Huntingtin Lowering

ABBV-951 Gets Another CRL, Pitolisant Approved for Pediatric Narcolepsy, FDA Clears Efgartigimod for CIDP

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

Stem Cells of Secondary Progressive Multiple Sclerosis Drive Increased Proinflammatory T-Cell Activity

Postmortem Analysis Reveals Distinct Patterns of Aquaporin-4 in Parkinson Disease and Multiple System Atrophy

EMA Approves Semaglutide as First GLP-1 RA for Cardiovascular, Stroke-Related Benefits

Recognizing Macromastia in Women as a Potential Risk Factor for Headache: Kristyn Pocock, MD

Optimizing Speech and Movement Therapy to Improve Motor and Nonmotor Symptoms of Parkinson Disease: Cynthia Fox, PhD, CCC-SLP